Page 2 - Sanket Koul

Eco Survey flags need for skill courses to curb dropouts in classes 9-12

The Economic Survey 2025 calls for skill-embedded education in classes 8-12 to tackle high dropout rates driven by income pressure and limited access to secondary schools

Eco Survey urges education reforms, global push to curb student exodus

India must reform higher education and promote international student programmes to curb brain drain and boost its global education presence

Centre puts stricter controls on pregabalin sales over abuse concerns

India has moved pregabalin to Schedule H1, tightening prescription and record-keeping norms after states flagged widespread misuse of the nerve pain drug for intoxication

Centre scraps prior approval system for BA/BE studies of low-risk drugs

The health ministry has amended clinical trial rules to replace prior approvals for low-risk BA/BE studies with simple online intimations, a move aimed at cutting delays, easing compliance

India-EU FTA: Indian pharma to get stronger dose of EU market access

EU's zero-tariff offer on most chemical and medical exports is set to boost India's pharma, medtech and biosimilars access to European markets

India-EU FTA boosts Europe's appeal for Indian students amid visa flux

India-EU FTA's focus on mobility could expand choices for Indian students, making Europe a more deliberate study destination even as the US remains key amid uncertainty over visa policies

Antimicrobial sales growth set to temper in 2026 over govt's AMR push

Stricter rules to curb antimicrobial resistance may limit antibiotic sales growth in 2026, as India tightens OTC use and pushes prescription-led, responsible consumption

Centre mandates blue chip on all antimicrobial brand labels to counter AMR

In a gazette notification dated January 23, the Union health ministry proposed adding a new clause under Rule 95 of the Drugs Rules, 1945

Syngene downgrades its revenue guidance by 5% on Librela inventory impact

Syngene trims FY26 revenue guidance by up to 5% as inventory correction for veterinary drug Librela hits profits, even as core research and CDMO business grows

DLF gears for senior housing entry, eyes sales in Mumbai, Panchkula in FY27

Developer says Q3 sales dropped due to Dahlias pause, no new launches

DLF Q3 FY26 results: PAT up 13.6%, revenue rises 42% on high net income

Realty major states gross zero debt on high net cash position

Zydus Lifesciences launches cancer drug Nivolumab's biosimilar in India

Move comes just months before nivolumab patent expiry in India on May 2, 2026

Budget 2026: Developers demand targeted tax reforms to spur housing demand

Ahead of Budget 2026, realtors seek higher home loan tax deductions, a wider affordable housing definition, and dispute-resolution reforms to revive housing demand

CDSCO flags 7 drugs as spurious, 167 fail quality tests in Dec 2025

CDSCO has flagged seven drug batches as spurious and listed 167 others as not of standard quality in its December 2025 surveillance, covering common medicines for BP, pain and allergies

Centre halves review period for applications to conduct new drug trials

The health ministry has amended the NDCT Rules to cut approval timelines for new drug trials and testing by half, aiming to speed up innovation while easing regulatory processes for most applications

Dr Reddy's Q3 PAT down 14% Y-o-Y on low Lenalidomide sales in US

Dr Reddy's Laboratories reported a sharp fall in December-quarter profit as declining Lenalidomide sales in the US weighed on earnings, even as India revenues and branded businesses remained resilient

Elan Group awards ₹840 crore construction contract to Tata Projects

Elan Group awards an Rs 840 crore construction contract to Tata Projects for its ultra-luxury residential project 'Elan-The Statement' in Sector 49, Gurugram

High demand for luxury units drives housing segment premiumisation

Units priced ₹1 crore and above increase market share to 63% of total units sold in 2025

JB Pharma Q3 PAT up 22%, revenue rises 11% on better domestic performance

JB Pharma reports a 22% rise in Q3 FY26 profit as strong growth in domestic and international formulations offsets flat CDMO revenues

Residential assets lead as Gurugram attracts ₹86K cr investments in 2025

With ₹86,588 crore in projects cleared in 2025, Gurugram cements its place as India's hottest real estate hub-spanning premium homes, IT parks and mass housing